If you have been harmed by Benicar (olmesartan medoxomil), you may be eligible to receive part of the $300 million that Daiichi Sankyo Inc. and Forest Laboratories Inc. have already agreed to pay to settle claims, but you must act quickly. According to the terms of the settlement, you must have a retainer agreement with a Benicar attorney by … [Read more...]
Endo Pharmaceuticals Forced to Take “Extended-Release” Medication Off the Market
Opioid manufacturers have suffered a number of setbacks over the last several weeks. The FDA asked Endo Pharmaceuticals, in June, to stop the sale of Opana ER, an “extended-release” opioid pain reliever (OPR). If not, the agency promised it would no longer approve the drug. Endo indicated it would fully consider the request before acting. Then on … [Read more...]
What You Don’t Know About Generic Drugs, and How It Can Hurt You
The Danger of Generic Drugs It is very common for people to conflate generic drugs with their brand-name counterparts, but according to Jeremy Greene, a historian of medicine at Johns Hopkins, “The average American has a series of assumptions about generic and brand-name drugs that don’t hold up to historical scrutiny.” This conflation will … [Read more...]
Invokana: Big jolt for J&J
The giant pharmaceutical conglomerate Johnson & Johnson (J&J) has faced some serious allegations this year with respect to its most promising star product Invokana. The company had sales of $71.9 billion for the full-year 2016, an increase of 2.6% compared with its 2015 sales. Sales soared due to millions spent by the company in promoting … [Read more...]
Taxotere MDL 2740: A Slow But Strong Start
Taxotere is a cytotoxic chemotherapy drug and is the brand name for docetaxel generic form. In 1996, Sanofi-Aventis won approval for Taxotere to be marketed in the U.S. for the treatment of various cancers: breast cancer, advanced stomach cancer, head and neck cancer, non-small cell lung cancer and metastatic prostate cancer. Taxotere sales went as … [Read more...]
- 1
- 2
- 3
- …
- 35
- Next Page »
Recent Comments